Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dolby Laboratories (DLB) Total Liabilities (2016 - 2025)

Dolby Laboratories (DLB) has disclosed Total Liabilities for 17 consecutive years, with $589.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 8.16% year-over-year to $589.3 million, compared with a TTM value of $589.3 million through Dec 2025, down 8.16%, and an annual FY2025 reading of $605.2 million, down 2.86% over the prior year.
  • Total Liabilities was $589.3 million for Q4 2025 at Dolby Laboratories, down from $605.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $646.0 million in Q1 2025 and bottomed at -$2.6 billion in Q2 2025.
  • Average Total Liabilities over 5 years is $385.3 million, with a median of $519.1 million recorded in 2021.
  • The sharpest move saw Total Liabilities surged 38.55% in 2023, then crashed 596.81% in 2025.
  • Year by year, Total Liabilities stood at $462.4 million in 2021, then decreased by 1.38% to $456.0 million in 2022, then increased by 25.71% to $573.2 million in 2023, then increased by 11.92% to $641.6 million in 2024, then fell by 8.16% to $589.3 million in 2025.
  • Business Quant data shows Total Liabilities for DLB at $589.3 million in Q4 2025, $605.2 million in Q3 2025, and -$2.6 billion in Q2 2025.